QUICK ANSWER · AEO / GEO
A melanocortin-derived tripeptide with predominantly preclinical evidence and no established human therapeutic efficacy.
ENTITY FACTS
What should readers identify first?
What remains unknown?
- human pharmacokinetics, pharmacodynamics, efficacy and safety for every route
- molecular target and the role of PepT1 or melanocortin receptors in clinical settings
- whether effects in mouse colitis models translate to ulcerative colitis or Crohn's disease
- identity, purity, aggregation and sterility of products marketed under the KPV name
- long-term immunogenicity, reproductive and carcinogenic risks
- final PCAC vote documentation and FDA decision following the July 2026 meeting
What limits these conclusions?
- There are no verified human exposure studies. Human cell cultures and excised human skin are laboratory models, while disease findings come mainly from mice. Formulation studies confound KPV with nanoparticles, hydrogels or barrier-disrupting delivery. FDA also found major identity and quality-characterization gaps for free base and acetate. Therefore clinical benefit, route-specific safety and product equivalence remain unestablished.
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
- https://www.fda.gov/media/193346/download
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- https://pubmed.ncbi.nlm.nih.gov/18092346/
- https://pubmed.ncbi.nlm.nih.gov/18061177/
- https://pubmed.ncbi.nlm.nih.gov/28343991/
- https://pubmed.ncbi.nlm.nih.gov/15102092/
- https://pubmed.ncbi.nlm.nih.gov/27458604/
- https://pubmed.ncbi.nlm.nih.gov/28143741/
- https://products.mhra.gov.uk/
FAQ · ANSWER ENGINE
Frequently asked questions
What is KPV?
KPV is described pharmacologically as Experimental melanocortin-derived tripeptide / anti-inflammatory research. A melanocortin-derived tripeptide with predominantly preclinical evidence and no established human therapeutic efficacy.
Does KPV have strong evidence?
PrimeCoreBio records Evidence Grade E. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is KPV approved everywhere?
No global conclusion should be inferred. PrimeCore Class C must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.